The Office of Fair Trading (OFT) has carried out an evaluation of its abuse of dominance decision in the Napp Pharmaceuticals case (Napp) and found that it had a considerable impact on the market for sustained release morphine (SRM) tablets in the UK. In 2001, the OFT found that Napp had abused its dominant position in the supply of SRM tablets and capsules in the UK. Napp had been charging excessively low prices in the hospital sector but charging excessively high prices in the community sector. The OFT ordered that Napp price fairly and competitively in both sectors and reduce the hospital and community price differential. The OFT evaluated its decision and found, amongst other things, that in the hospital sector, Napp has removed its exclusionary discounts and increased its prices allowing competitors to compete. In addition, Napp’s market share has fallen from 95 per cent to 50 per cent. In the community sector, Napp’s prices have reduced by around 25 per cent, although its SRM products are still more expensive than its rivals’. Its market share in the community sector has fallen from 95 per cent to 65 per cent. The price differential between community and hospital prices has also reduced. The OFT estimates the intervention has created net annual savings in the region of £1.5m.